Victoria Socha

DocwireNews

&nbsp;Astellas Pharma, Inc. and FibroGen, Inc. announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion regarding the use of roxadustat for the treatment of adults with symptomatic anemia associated with chronic kidney disease (CKD). Worldwide, one in ten individuals is impacted by CKD; one in five of those are affected by anemia. Anemia in CKD, which is often untreated, is associated with significant decline in quality of life and increased risk of progression to adverse cardiovascular and renal outcomes.If the European Commission approves roxadustat, it will be first orally administered inhibitor of hypoxia-inducible factor prolyl hydroxylase available in Europe. Roxadustat activates the body&rsquo;s natural response to reduced levels of oxygen in the blood, a response that involves regulation of multiple, coordinated processes that lead to the correction of anemia and a reduction in the need for intravenous iron.Bernhardt G. Zeiher, MD, chief medical officer at Astellas Pharma, Inc., said, &ldquo;Anemia of CKD remains an under-recognized and under-treated condition. Today&rsquo;s positive CHMP opinion marks a significant step in providing patients with a new and important treatment option for anemia associated with CKD, regardless of dialysis status. We look forward to the review and assessment by the European Commission (EC), which, if positive, would make roxadustat the first HIF-PH inhibitor approved in Europe to treat symptomatic anemia in adult patients with CKD.&rdquo;Mark Eisner, MD, MPH, chief medical officer at FibroGen, said, &ldquo;Anemia of CKD significantly affects the daily lives of those living with the condition. Roxadustat&rsquo;s novel mechanism of action and oral administration provide physicians with the opportunity to help redefine the management of symptomatic anemia of CKD.&rdquo;The positive position from the CHMP will be reviewed by the EC, which has the authority to approve medicines for the European Union member states, as well as Iceland, Norway, Liechtenstein, and Northern Ireland. The EC has 67 days from the CHMP opinion to issue a final decision.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Positive Opinion from CHMP of Roxadustat for CKD-Associated Anemia

Chronic Kidney Disease

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe